Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene Therapy's Future Can Be NAV-igated Alone, REGENXBIO CEO Says

This article was originally published in Scrip

Executive Summary

Having netted $148m in its September initial public offering, REGENXBIO, Inc. is moving toward the clinic with its first two gene therapy candidates and believes it – and its licensees – are positioned to succeed in gene therapy where earlier attempts failed. Coming out of a "quiet period" after its IPO, which sold 7.2 million shares at $22 apiece, REGENXBIO CEO Kenneth Mills talked to Scrip's sister publication "The Pink Sheet" DAILY about his company's plans and strategies, as well as why its novel adeno-associated virus (NAV) vectors might be more viable than the first iteration of AAV-based therapies.

You may also be interested in...

Biogen Shores Up Gene Therapy Ambitions With New Deal

Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.

Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.

Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients

Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts